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Abstract: [18F]FluorTriopride ([18F]FTP) is a dopamine D3-receptor preferring radioligand with potential for investiga-
tion of neuropsychiatric disorders including Parkinson disease, dystonia and schizophrenia. Here we estimate hu-
man radiation dosimetry for [18F]FTP based on the ex-vivo biodistribution in rodents and in vivo distribution in nonhu-
man primates. Biodistribution data were generated using male and female Sprague-Dawley rats injected with ~370 
KBq of [18F]FTP and euthanized at 5, 30, 60, 120, and 240 min. Organs of interest were dissected, weighed and 
assayed for radioactivity content. PET imaging studies were performed in two male and one female macaque fas-
cicularis administered 143-190 MBq of [18F]FTP and scanned whole-body in sequential sections. Organ residence 
times were calculated based on organ time activity curves (TAC) created from regions of Interest. OLINDA/EXM 1.1 
was used to estimate human radiation dosimetry based on scaled organ residence times. In the rodent, the high-
est absorbed radiation dose was the upper large intestines (0.32-0.49 mGy/MBq), with an effective dose of 0.07 
mSv/MBq in males and 0.1 mSv/MBq in females. For the nonhuman primate, however, the gallbladder wall was the 
critical organ (1.81 mGy/MBq), and the effective dose was 0.02 mSv/MBq. The species discrepancy in dosimetry 
estimates for [18F]FTP based on rat and primate data can be attributed to the slower transit of tracer through the 
hepatobiliary track of the  primate compared  to the rat, which lacks a gallbladder.  Out findings demonstrate that 
the nonhuman primate model is more appropriate model for estimating human absorbed radiation dosimetry when 
hepatobiliary excretion plays a major role in radiotracer elimination. 
Keywords: [18F]FluorTriopride, PET, dosimetry, Fluorine-18, D3 receptors, Parkinson disease
Introduction
[18F]FluorTriopride ([18F]FTP) is a unique dopa-
mine D3-receptor (D3R) preferring radioligand 
with potential for investigation of neuropsychi-
atric disorders including Parkinson disease, 
dystonia and schizophrenia. D3R belongs to 
the family of D2-like receptors (D2R, D3R, 
D4R), which are coupled to Gi and inhibit adenyl 
cyclase [1, 2]. D3R like D2R are expressed in 
striatum, but the data suggest that D3R is 
expressed predominantly in ventral (limbic) and 
to a lesser (although still substantial) degree in 
dorsal (motor) striatum [3]. Various studies sug-
gest that D2R and D3R may be regulated differ-
ently in Parkinson disease [4-6], schizophrenia 
[7, 8], and substance abuse [9, 10]. Recent 
data also hint toward abnormalities in striatal 
D3R in dystonia [11]. One of the major obsta-
cles to better understanding of the D2R/D3R 
dynamic in such conditions has been lack of 
selective ligands for in vivo molecular imaging 
studies. Among numerous D2-like receptor 
ligands, only [18F](N-methyl)benperidol (NMB) 
provides specificity for D2R, with a 200-fold 
selectivity for D2R versus D3R [11]. We have 
recently validated a new radioligand [18F]FTP 
which has a 160-fold selectivity for D3R versus 
D2R [12]. The objective of this study is to deter-
mine the organ distribution of [18F]FTP in rodent 
and nonhuman primate species of animals to 
estimate human absorbed radiation dosimetry. 
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Specifically, we used ex-vivo biodistribution ex- 
periments in Sprague-Dawley rats and noninva-
sive PET imaging studies of tissue kinetics in 
macaque fascicularis. These dosimetry esti-
mates will facilitate application of [18F]FTP for 
PET imaging studies of D3 receptors in human 
subjects.
Materials and methods
Radiopharmaceutical preparation
[18F]FTP was prepared using an automated sys-
tem based on published synthetic methods 
[12-14]. [18F]Fluoride was produced by the 
18O(p, n)18F nuclear reaction induced on an iso-
topically-enriched [18O]water target using the 
Washington University RDS Eclipse cyclotron. A 
nucleophilic displacement reaction was used to 
synthesize [18F]FTP starting with the corre-
sponding mesylate and [18F]fluoride. The radio-
labeled product was isolated using semi-pre-
parative HPLC. [18F]FTP was reformulated in 
ethanolic saline for Injection, USP (1/10 v/v) 
and sterilized by terminal filtration. The radio-
chemical purity of the radiopharmaceutical 
product was over 95%, and the end-of-synthe-
sis specific activity exceeded 74 TBq/mmol. 
Animal protections 
All applicable international, national, and insti-
tutional guidelines for the care and use of 
rodents and nonhuman primates were fol-
lowed. Procedures used in this work were 
approved by the Animal Studies Committee of 
Washington University in Saint Louis.
Rodent biodistribution 
Twenty male (200-245 gram) and 20 female 
(170-210 gram) Sprague Dawley rats were 
administered ~370 KBq of [18F]FTP in 100 µL 
via intravenous tail vein injection. The animals 
were maintained in metabolic cages for collec-
tion of  urine and feces excretion. Animals were 
euthanized in groups of four at: 5 min, 30 min, 
60 min, 120 min, and 240 min post injection of 
[18F]FTP. The organs were harvested, and the 
percent injected dose per gram (%ID/gram) was 
determined by measuring the radioactivity in 
weighed samples, and comparison to that of a 
standard sample of the injectate. 
The organ residence times were calculated by 
numerical integration (trapezoid method) of the 
time activity data expressed in %ID/gram of tis-
sue. The following initial organ activity immedi-
ately after injection was assumed based on the 
respective blood volumes: lungs, 5.9%; liver, 
2.9%; spleen and kidneys, each 1.5%; bone, 
3.7%. The remainder of activity (72%) was 
assigned to the blood compartment. Blood and 
bone mass were assumed to be 8% and 15% of 
the total body mass, respectively.
The cumulative activities (%ID) in the urine and 
feces activities were plotted as a function of 
time, and an uptake function [F(t) = A0 (1-exp(-
A1 t))] was fitted to the data. We then calculated 
a bladder residence time using the values of A0 
and A1 in the MIRD bladder voiding model, 
assuming a voiding interval of 1 hr. The animal 
organ residence times were scaled to human 
organ weights according to the “relative organ 
mass scaling” method [15]. 
The above technique was employed for all 
organs except the small and large intestines, 
due to the high accumulation of radioactivity in 
these organs. We instead applied the percent 
injected dose in the entire organs as measured 
in the animal biodistribution experiments. The 
remainder of the body residence time was cal-
culated as 70% of the injected activity deposit-
ed in blood, fat and all other unaccounted tis-
sues. The remainder was defined as the maxi-
mum residence time of F-18 activity minus the 
Figure 1. Schematic of data acquisition in primates 
using small animal PET imaging. Seven to eight suc-
cessive PET scans of increasing duration were ob-
tained in four positions: A (whole brain), B (heart and 
lungs), C (liver, gallbladder and kidneys), and D (uri-
nary bladder, small and large intestines).
Dosimetry study of a D3 receptor PET radioligand [
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Table 1. Biodistribution of [18F]FTP in male Sprague-Dawley rats expressed as percent injected dose 
per gram of tissue (%ID/g). Each set of data is the mean ± SD for n = 4 animals at each time point
5 min 30 min 1 hour 2 hours 4 hours
Blood 0.176 ± 0.041 0.176 ± 0.012 0.146 ± 0.015 0.068 ± 0.056 0.070 ± 0.013
Lung 5.948 ± 0.354 1.601 ± 0.057 0.497 ± 0.075 0.205 ± 0.178 0.183 ± 0.023
Liver 2.999 ± 0.414 2.257 ± 0.362 1.359 ± 0.094 0.611 ± 0.515 0.707 ± 0.084
Spleen 2.693 ± 0.830 1.350 ± 0.248 0.480 ± 0.102 0.169 ± 0.147 0.165 ± 0.014
Kidney 3.725 ± 0.321 2.513 ± 0.203 1.733 ± 0.225 0.679 ± 0.550 0.770 ± 0.024
Muscle 0.176 ± 0.027 0.182 ± 0.022 0.094 ± 0.011 0.046 ± 0.038 0.048 ± 0.007
Fat 0.130 ± 0.018 0.189 ± 0.039 0.105 ± 0.021 0.043 ± 0.039 0.026 ± 0.003
Heart 1.169 ± 0.185 0.353 ± 0.025 0.195 ± 0.023 0.084 ± 0.071 0.078 ± 0.010
Brain 0.257 ± 0.023 0.171 ± 0.010 0.134 ± 0.010 0.064 ± 0.054 0.083 ± 0.011
Bone 0.564 ± 0.053 0.413 ± 0.020 0.249 ± 0.017 0.158 ± 0.132 0.292 ± 0.025
Marrow 0.836 ± 0.214 0.689 ± 0.042 0.412 ± 0.038 0.143 ± 0.127 0.084 ± 0.034
Testes/Uterus 0.152 ± 0.014 0.223 ± 0.010 0.202 ± 0.011 0.119 ± 0.101 0.119 ± 0.017
Prostate/Ovaries 0.587 ± 0.247 0.734 ± 0.086 0.736 ± 0.310 0.340 ± 0.326 0.088 ± 0.084
Adrenals 3.767 ± 1.049 5.838 ± 0.698 3.868 ± 1.002 1.806 ± 1.551 0.798 ± 0.345
Thyroid 0.863 ± 0.158 0.305 ± 0.209 0.238 ± 0.004 0.097 ± 0.078 0.127 ± 0.031
Pancreas 1.893 ± 0.208 1.094 ± 0.062 0.398 ± 0.067 0.121 ± 0.106 0.095 ± 0.016
Thymus 0.838 ± 0.081 0.695 ± 0.052 0.511 ± 0.057 0.225 ± 0.185 0.158 ± 0.030
Stomach 0.372 ± 0.129 0.410 ± 0.085 0.344 ± 0.079 0.170 ± 0.163 0.057 ± 0.017
Small intestine 3.239 ± 0.500 4.986 ± 0.959 3.283 ± 1.191 0.848 ± 0.730 0.392 ± 0.038
Upper large intestine 0.703 ± 0.067 2.718 ± 0.972 9.278 ± 1.151 7.996 ± 6.584 1.645 ± 0.565
Lower large intestine 0.234 ± 0.007 0.202 ± 0.013 0.255 ± 0.048 0.356 ± 0.356 6.296 ± 1.053
Table 2. Biodistribution of [18F]FTP in female Sprague-Dawley rats expressed as percent injected dose 
per gram of tissue (%ID/g). Each set of data is the mean ± SD for n = 4 animals at each time point
5 min 30 min 1 hour 2 hours 4 hours
Blood 0.176 ± 0.041 0.176 ± 0.012 0.146 ± 0.015 0.068 ± 0.056 0.070 ± 0.013
Lung 5.948 ± 0.354 1.601 ± 0.057 0.497 ± 0.075 0.205 ± 0.178 0.183 ± 0.023
Liver 2.999 ± 0.414 2.257 ± 0.362 1.359 ± 0.094 0.611 ± 0.515 0.707 ± 0.084
Spleen 2.693 ± 0.830 1.350 ± 0.248 0.480 ± 0.102 0.169 ± 0.147 0.165 ± 0.014
Kidney 3.725 ± 0.321 2.513 ± 0.203 1.733 ± 0.225 0.679 ± 0.550 0.770 ± 0.024
Muscle 0.176 ± 0.027 0.182 ± 0.022 0.094 ± 0.011 0.046 ± 0.038 0.048 ± 0.007
Fat 0.130 ± 0.018 0.189 ± 0.039 0.105 ± 0.021 0.043 ± 0.039 0.026 ± 0.003
Heart 1.169 ± 0.185 0.353 ± 0.025 0.195 ± 0.023 0.084 ± 0.071 0.078 ± 0.010
Brain 0.257 ± 0.023 0.171 ± 0.010 0.134 ± 0.010 0.064 ± 0.054 0.083 ± 0.011
Bone 0.564 ± 0.053 0.413 ± 0.020 0.249 ± 0.017 0.158 ± 0.132 0.292 ± 0.025
Marrow 0.836 ± 0.214 0.689 ± 0.042 0.412 ± 0.038 0.143 ± 0.127 0.084 ± 0.034
Testes/Uterus 0.152 ± 0.014 0.223 ± 0.010 0.202 ± 0.011 0.119 ± 0.101 0.119 ± 0.017
Prostate/Ovaries 0.587 ± 0.247 0.734 ± 0.086 0.736 ± 0.310 0.340 ± 0.326 0.088 ± 0.084
Adrenals 3.767 ± 1.049 5.838 ± 0.698 3.868 ± 1.002 1.806 ± 1.551 0.798 ± 0.345
Thyroid 0.863 ± 0.158 0.305 ± 0.209 0.238 ± 0.004 0.097 ± 0.078 0.127 ± 0.031
Pancreas 1.893 ± 0.208 1.094 ± 0.062 0.398 ± 0.067 0.121 ± 0.106 0.095 ± 0.016
Thymus 0.838 ± 0.081 0.695 ± 0.052 0.511 ± 0.057 0.225 ± 0.185 0.158 ± 0.030
Stomach 0.372 ± 0.129 0.410 ± 0.085 0.344 ± 0.079 0.170 ± 0.163 0.057 ± 0.017
Small intestine 3.239 ± 0.500 4.986 ± 0.959 3.283 ± 1.191 0.848 ± 0.730 0.392 ± 0.038
Upper large intestine 0.703 ± 0.067 2.718 ± 0.972 9.278 ± 1.151 7.996 ± 6.584 1.645 ± 0.565
Lower large intestine 0.234 ± 0.007 0.202 ± 0.013 0.255 ± 0.048 0.356 ± 0.356 6.296 ± 1.053
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Table 3. Organ residence times of [18F]FTP scaled 
to human males and females based on male and 
female rat biodistribution data
Organ Residence Time Males-(min)
Residence Time 
Females-(min)
Blood 5.2 ± 1.2 3.9 ± 0.5
Lung 8.2 ± 0.8 8.5 ± 1.9
Liver 18.8 ± 3.9 20.1 ± 3.5
Spleen 0.91 ± 0.24 1.15 ± 0.23
Kidney 3.4 ± 0.6 3.16 ± 0.49
Muscle 18.6 ± 4.3 11.0 ± 2.7
Fat 4.4 ± 1.3 3.19 ± 1.3
Heart 0.58 ± 0.11 0.56 ± 0.11
Brain 1.26 ± 0.25 1.05 ± 0.16
Bone 24.2 ± 4.5 18.57 ± 3.2
Marrow 2.73 ± 0.66 4.77 ± 1.1
Testes 0.05 ± 0.01
Prostate 0.064 ± 0.03
Adrenals 0.33 ± 0.11 0.233 ± 0.07
Thyroid 0.037 ± 0.012 0.039 ± 0.008
Pancreas 0.34 ± 0.05 0.35 ± 0.04
Thymus 0.061 ± 0.013 0.081 ± 0.01
Stomach 0.27 ± 0.106 0.54 ± 0.16
Small intestines 13.1 ± 5.6 14.0 ± 5.6
Upper large intestines 48.3 ± 25.2 68.8 ± 7.5
Lower large intestines 32.8 ± 3.1 38.6 ± 4.5
Uterus 0.21 ± 0.04
Ovaries 0.09 ± 0.02
Excreted 20 15
Remainder of the body 3.9 3.0
sum of observed residence times in specific 
organs minus the excreted residence time. 
The scaled human residence times from these 
rodent experiments were entered in the pro-
gram OLINDA/EXM 1.1 for F-18 in  the adult 
human male and female anthropomorphic 
models [16].
Nonhuman primate tissue distribution
Two male and a female macaque fascicularis 
underwent whole-body scanning for approxi-
mately 3 hrs using a Siemens MicroPET-F220. 
The animals weighed 7.2 (male 1), 6.4 (male 2) 
and 4.5 (female) kg, and received 167, 176 and 
143 MBq of [18F]FTP respectively. The first ani-
mal (male 1) was scanned twice, and received 
190 MBq of [18F]FTP for the second scan. The 
animals were prepared for imaging as previ-
ously described [17, 18].
Data acquisition
Prior to radioligand injection, we collected 
four 30 min transmission scans to cover 
four body sections: A (whole brain), B (heart 
and lungs), C (liver, gallbladder and kidneys), 
and D (urinary bladder, small and large 
intestines). Starting immediately after i.v. 
injection of [18F]FTP, seven to eight sequen-
tial PET scans were performed for each of 
the four sections (Figure 1). No loss of urine 
or fecal matter was observed in the animals 
during the scans. For one of the animals 
(male 1), arterial blood samples were 
obtained during a total scanning session of 
approximately 4 hrs. Most of the blood sam-
ples were taken in the first 3 min to ensure 
adequate description of the total radioactiv-
ity within the arterial blood compartment, 
Afterwards, longer sampling times were 
used over the 4 hrs study. The radioactivity 
content in each blood sample was mea-
sured in a well counter that was cross-cali-
brated with the PET scanner. 
PET image analysis
The reconstructed image resolution at the 
center of the field of view for the PET studies 
was < 2.0 mm full width half maximum 
(FWHM) for all 3 dimensions. PET image 
counts were calibrated to a dose calibrator 
to facilitate comparison of PET measure-
ments to MBq of F-18. For some organs 
(whole brain, heart, lungs, urinary bladder), 
regions of interest (ROIs) were drawn to en- 
tirely encompass the organ using ASIPro 
VM™ MicroPET analysis software (Siemens 
PreClinical Solutions, Knoxville, TN). For others 
(liver, kidney, and gallbladder), we could not 
delineate an appropriate ROI. Hence, we chose 
several small representative ROIs that con-
tained the highest observed radioactivity con-
centrations within the specific organ. The aver-
age radioactivity concentrations of these repre-
sentative ROIs were multiplied by the entire 
organ weight to give a liberal estimate of the 
radioactivity within the total organ. This 
approach will lead to slight overestimation of 
the organ values, but the error in the estimate 
tends toward increased subject safety.  
The calculated activity in the whole organ was 
plotted as a function of time to yield the organ 
Dosimetry study of a D3 receptor PET radioligand [
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activity. The urinary bladder time activity curve 
was also fitted with an uptake function to pro-
vide the MIRD bladder model parameters need-
ed to calculate the bladder activity residence 
time. For this estimation, 2 hrs bladder voiding 
intervals were used.
The blood time-activity curve for nonhuman pri-
mate data was integrated using the trapezoidal 
rule to yield the blood residence time. The 
blood activity in units of MBq/mL was convert-
ed to percent injected dose assuming a blood 
volume of 8% of body weight and the injected 
dose (175.5 MBq). Finally, 5% of the blood vol-
ume was assumed to be present in the left ven-
tricle at all times.
The calculated residence times (T) were scaled 
from animal to human based on the equation: 
T T M
M
M
M
human
body
human
organ
animal
organ
animal
body
human animal= c cm m                    (1)
Where T is the residence time and M is the 
mass (organ or total body). 
We used human male and female organ weights 
in OLINDA/EXM [19] for the adult male and 
adult female models. The percentage body 
weight was applied for the kidney, liver, and 
heart as reported previously for male and 
female macaque fascicularis [20]. We used the 
gallbladder and bladder percentages of total 
body weight as determined ex vivo in the past, 
and the organ weights for the brain and lungs 
were based on their measured volume and an 
assumed density of 1.0 g/cm3. 
The scaled human residence times were 
entered in the program OLINDA/EXM 1.1 for 
F-18 following the adult human male and 
female anthropomorphic models, with the 
assumption that 10% of the blood residence 
time is in the heart and bone activity is equal 
Figure 2. Blood time-activity curves for [18F]FTP expressed in percentage of 
injected dose (%ID) per organ in male (A) and female (B) rats (n = 4 at each 
time point).
Table 4. Estimated human absorbed radiation 
dose for [18F]FTP (mSv/MBq) from rodent biodis-
tribution data
Organ
Dose (mSv/MBq)
Males Females
Adrenals 0.06 0.06
Brain 0.01 0.01
Breasts 0.01 0.01
Gallbladder wall 0.03 0.04
Lower large intestine wall 0.34 0.43
Small Intestines wall 0.08 0.11
Stomach Wall 0.02 0.02
Upper large intestine wall 0.33 0.48
Heart muscle 0.01 0.02
Kidneys 0.05 0.05
Liver 0.05 0.06
Lungs 0.03 0.04
Muscle 0.01 0.01
Ovaries 0.00 0.09
Pancreas 0.02 0.03
Red Marrow 0.02 0.03
Bones (osteogenic cells) 0.04 0.04
Skin 0.01 0.01
Spleen 0.02 0.01
Testes 0.01 0.00
Thymus 0.01 0.02
Thyroid 0.01 0.01
Urinary bladder wall 0.05 0.05
Uterus 0.02 0.04
Total Body 0.01 0.02
Table 5. Estimated effective dose and effec-
tive dose equivalent for [18F]FTP in human adult 
males and females based on the rodent biodistri-
bution data
Males Females
Effective Dose (mSv/MBq) 0.07 0.1
Effective Dose Equivalent (mSv/MBq) 0.064 0.1
time-activity curves. Organ 
residence times were comput-
ed from the analytical integra-
tion of the multi-exponential 
fitted onto the decay-correct-
ed time-activity curves using 
GraphPad Prism6 software. 
The maximum theoretical resi-
dence time (T1/2/ln(2) = 2.64 
hrs for F-18) minus the sum of 
measured residence times 
was assigned to the remain-
der of the body as unspecific 
Dosimetry study of a D3 receptor PET radioligand [
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part cortical and trabecular. The content within 
the intestines was used as the source of 
absorbed radiation to the intestines.
Results
Rodent biodistribution
The male and female rat biodistribution data 
are presented in Tables 1 and 2, respectively. 
The data is very similar for the two species. 
Both show predominant accumulation of radio-
activity in the small intestines which peaks at 
30 minutes, followed by accumulation in the 
upper large intestine that is maximum at about 
1 hr. There was relatively modest localization of 
activity in liver and kidney.
Residence times and dosimetry from rodent 
biodistribution data
Organ residence times scaled to human organ 
weights are presented in Table 3. In The largest 
residence times were observed in the small 
and large intestines. Otherwise, the internal 
organ with the largest accumulation was the 
liver. The residence time in the blood was low at 
approximately 0.17 min and was characterized 
by a single exponential clearance with a biologi-
cal half-life of 173 min for both male and female 
groups (n = 4 at each time point) (Figure 2). 
For the male group, the fit on urine data pro-
vided A0 = 22%ID and A1 = 0.90 hr
-1 with a blad-
der residence time of 4.6 min and an excreted 
residence time of 20.0 min. The fit on the feces 
data provided A0 = 0.07%ID and A1 = 0.5 hr
-1 
with an excreted residence time of 0.063 min. 
Combined data for urine and feces resulted in 
an excreted residence time of 20 min. For the 
female group, the fit of the urine data provided 
A0 =15%ID and A1 = 1.12 hr
-1 with a bladder 
residence time of 2.85 min and an excreted 
residence time of 14.9 min. The fit of the feces 
data provided A0 = 0.04%ID and A1 = 0.75 hr
-1 
with an excreted residence time of 0.042 min. 
Combined data for urine and feces resulted in 
an overall excreted residence time of 15 min.
Estimates of human organ absorbed radiation 
doses for the adult human male and female are 
presented in Tables 4 and 5, respectively. The 
uncertainty of the dose estimates is propor-
tional to the uncertainties in the respective 
organ residence times.
Nonhuman primate biodistribution 
The representative sagittal image of [18F]FTP 
indicates the macaque fascicularis has relative 
high gallbladder uptake within 10 min data col-
lection at 190 min post injection shown in 
Figure S1A and representative transverse 
Figure 3. Different tissue 
time-activity curves for [18F]
FTP. Decay-corrected activ-
ity is expressed as a per-
centage of injected dose 
(%ID) per different organ of 
a representative macaca 
fascicularis.
Figure 4. Blood time-activity curve based on arterial 
blood sampling in a male macaca fascicularis follow-
ing the intravenous injection of [18F]FTP.
Dosimetry study of a D3 receptor PET radioligand [
18F]FTP 
307 Am J Nucl Med Mol Imaging 2016;6(6):301-309
image of [18F]FTP indicates animal has high 
lung uptake with 2 min data collection begin-
ning 6 min post injection Figure S1B. 
Figure 3 shows the time activity curves com-
piled from sequential imaging of a male maca-
ca fascicularis. The time activity data were fit-
ted with a function composed of single or com-
bined exponentials. Least square minimization 
was performed to find the best fitting para- 
meters.
Residence times and dosimetry estimation
The time-activity data for blood was collected 
for the second male macaca fascicularis only, 
and is shown in Figure 4. We calculated a heart 
chamber residence time of 0.091 min based on 
the blood residence time of 1.82 min, a value 
that was employed for all the animals. The cal-
culated residence times are reported in Table 
6. 
Human adult male and female absorbed radia-
tion dosimetry was estimated from data derived 
from residence times for the animals and the 
OLINDA/EXM model. These data are presented 
in Table 7. 
mSv/MBq in male and 0.1 mSv/MBq in female. 
Although the rodent data indicates a maximum 
injected dose of 480 MBq to correspond to an 
effective dose (ED) below 50 mSv, the radiation 
dose to the intestes is the dose limiting factor. 
Indeed, the rat model projects an injected dose 
of 111 MBq will result in a radiation dose of 
approximately 50 mGy to the intestinal wall, 
with less than 30 mGy delivered to the gonads, 
red marrow or whole body.
By contrast, data from the imaging studies of 
nonhuman primate demonstrated high reten-
tion of the radiotracer in the liver and gallblad-
der, indicating predominant hepatobiliary clear-
ance. The image data from the macaque stud-
ies demonstrate a much longer residence time 
in the liver, and the absence of activity in the 
intestines. These findings reflect the much 
slower transfer of [18F]FTP and/or its radioac-
tive metabolites through the hepatobiliary track 
in primates compared to rodents. As a result of 
this difference in tracer disposition, the critical 
organ based on the  macaque data was the 
gallbladder wall (estimated human dose 2.78 
mGy/MBq) and a lower Effective Dose (0.02 
mSv/MBq) compared to estimates based on 
rodent data. An injected dose of 181 MBq of 
[18F]FTP will yield a an estimated human 
absorbed radiation dose of approximately 50 
mGy to the gallbladder,  and less than 30 mGy 
to the gonads, red marrow or whole body.
Conclusions
The human absorbed radiation dosimetry of 
new radiopharmaceutical can be estimated in 
preclinical studies of radiotracer disposition in 
Table 6. Organ residence times (hr) for [18F]FTP in based on 
PET image data from macaque fascicularis
Organ
Residence Time (hr)
#1  
(male)
#2 
(male)
#3  
(female)
Liver 1.85 1.27 1.83
Heart 0.02 0.09 0.02
Rain 0.04 0.05 0.07
Lungs 0.05 0.07 0.01
Gallbladder 0.15 0.02 0.38
Kidneys 0.13 0.19 0.11
Urinary bladder 0.13 0.06 0.21
Blood assigned to the left ventricle cavity 0.002 0.002 0.002
Remainder of the body 0.26 0.87 0.01
Table 7. Effective dose and effective dose 
equivalent for [18F]FTP in human adult males and 
females estimated from in vivo distribution data 
in macaque fascicularis
Males Females
Effective Dose (mSv/MBq) 0.26 0.37
Effective Dose Equivalent (mSv/MBq) 0.24 0.37
Discussion
Rat ex vivo biodistribution data 
showed that [18F]FTP was retained 
predominantly in the intestines, 
suggesting relatively rapid clear-
ance of the radioactivity from the 
liver into the small intestines and 
subsequent transfer to the large 
intestines. The organ having the 
largest absorbed radiation dose 
was the wall of the large intestines 
for both male and females, making 
the intestines the dose limiting 
organ (0.32-0.49 mGy/MBq). As 
an estimate of human dosimetry, 
the Effective Dose (ED) was 0.07 
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rodent and nonhuman primate. In these mea-
surements, it is important to be aware of spe-
cies differences when estimating human 
dosimetry. As this study of the D3 radioligand 
[18F]FTP shows, dramatic differences can arise 
in human dose estimates based on rodent and 
nonhuman primate models. The discrepancy 
between the critical organs estimated using 
rodent and nonhuman primate data most likely 
reflects the lack of a gallbladder in rodents. 
This crucial observation is a caveat against 
estimation of human dosimetry from rodent 
data for radiopharmaceuticals with hepatobili-
ary clearance.
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Figure S1. A. Representative Sagittal PET Image of [18F]FTP in the abdomen of monkey. Sagittal view through abdo-
men with left of image toward the abdominal wall and right of the image to the back. This is a PET image with 10 min 
data collection beginning with 190 min post [18F]FTP administration. The arrow indicates uptake of [18F]FTP in the 
gallbladder. The lower warm spot is in the bowel.  Warmer colors indicate higher uptake. The image is scaled to the 
slice maximum. The bony spine shows as white on the right of the attenuation image. B. Representative transverse 
PET Image of [18F]FTP in the abdomen of monkey. Transverse view through chest with top of the image toward the 
abdominal wall and bottom of the image to the back. This is a PET image with 2 min data collection beginning 6 
min after [18F]FTP administration. The arrow indicates the left lung. The animal is lying supine in the scanner which 
increases the blood flow toward the back (due to gravity). The lungs have high uptake of [18F]FTP in this early scan. 
Warmer colors indicate higher uptake. The image is scaled to the slice maximum.
